| 摘要 |
The invention relates to the use of at least one fumaric acid derivative as an NF-kappaB inhibitor for the treatment of diseases such as progressive systemic sclerodermia, mottled skin, Behet's disease, ulcerative colitis, vasculitis, osteoarthritis, gout, arteriosclerosis, Reiter's syndrome, types of encephelitis, endotoxin shock, pneumonia, encephalomyelitis, anorexia nervosa, hepatitis, mesangial nephritis, reperfusion syndrome, cytomegalvirus retinopathy, adenoviral diseases such as adenoviral catarrhal fever, AIDS, neuralgia, inflammatory demyelination polyneuropathy, multiplex type of mononeuropathy, mucoviscidosis, Bechterew's disease, endobrachyoesophagus, EBV (Epstein Barr virus) infection, interstitial cystitis, pancreatic diabetes type II, the radiation sensitisation of malignant tumours, and the multiple resistance of malignant cells in cancers. |
